好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Vascular Risk Prediction in Migraine: A Multimodality Risk Score Based on Artificial Intelligence-electrocardiogram Output, Echocardiography, and Detailed Migraine Characteristics
Headache
S23 - Hot Topics in Headache Medicine (2:12 PM-2:24 PM)
007

To develop a multimodality model to predict vascular risks in patients with migraine based on comprehensive clinical information, including artificial intelligence (AI)-electrocardiogram (ECG) output, echocardiogram parameters, and migraine characteristics.

Patients with migraine have higher risks for stroke and other adverse vascular events. We have conducted prior analyses on AI-ECG algorithms, echocardiogram parameters, and detailed migraine characteristics separately to predict vascular events. However, the relative importance and combined effects of each modality have not been established.

We conducted retrospective observational study on patients with at least one 12-lead ECG, transthoracic echocardiogram and a headache specialist visit at any Mayo Clinic site within 3 years. The outcome is a composite endpoint of acute ischemic stroke, acute myocardial infarction, venous thromboembolism, and all-cause mortality. We selected 20 risk parameters, including (a) demographics, (b) comorbidities, (c) AI-ECG output, (d) echocardiogram, (e) migraine characteristics found to be predictive of vascular events. Each variable was assigned a different risk score according to the hazard ratio (HR) and beta coefficient from prior Cox regression analysis. Additionally, a multivariate Cox regression was conducted to assess the relative risk of each parameter category.

We included 297 patients with migraine, of whom 247 were female and 109 had migraine with aura. The mean age was 39.0±13.3 and follow-up period was 68.9±60.9 months. Thirty-five developed the composite endpoint (11.8%). Those with a risk score ≥15 had significantly shorter vascular event-free survival (HR [95% CI], 3.85 [1.90–7.81]; p<0.001) compared to those scored <15. Furthermore, comorbidities (HR, 1.17 [1.06–1.30]; p=0.003) and migraine characteristics (HR, 1.34 [1.05–1.71]; p=0.018) were significantly predictive of the composite endpoint, whereas other categories were not.

This study supports the use of AI-ECG output, echocardiogram and migraine characteristics for vascular risk prediction, and highlights the importance of detailed migraine information for risk stratification.
Authors/Disclosures
Keiko Ihara, MD (Mayo Clinic)
PRESENTER
The institution of Dr. Ihara has received research support from American Heart Association.
Nan Zhang Nan Zhang has nothing to disclose.
Ping-Hao Yang, MD Dr. Yang has nothing to disclose.
Chieh-Ju Chao No disclosure on file
Francisco Lopez-Jimenez, MD The institution of Dr. Lopez-Jimenez has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Anumana. Dr. Lopez-Jimenez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Lopez-Jimenez has stock in Colibri . The institution of Dr. Lopez-Jimenez has received research support from Anumana. Dr. Lopez-Jimenez has received intellectual property interests from a discovery or technology relating to health care. Dr. Lopez-Jimenez has received publishing royalties from a publication relating to health care.
Kathryn Mangold, PhD Dr. Mangold has received intellectual property interests from a discovery or technology relating to health care.
Zachi Attia Zachi Attia has received personal compensation in the range of $0-$499 for serving as a Consultant for Anumana. Zachi Attia has received personal compensation in the range of $0-$499 for serving as a Consultant for XAI. Zachi Attia has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Pfizer.
Paul Friedman Paul Friedman has received intellectual property interests from a discovery or technology relating to health care. Paul Friedman has received intellectual property interests from a discovery or technology relating to health care. Paul Friedman has received intellectual property interests from a discovery or technology relating to health care.
Peter Noseworthy Peter Noseworthy has nothing to disclose.
Chia-Chun Chiang, MD (Mayo Clinic) Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aruene Corporation . Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. The institution of Dr. Chiang has received research support from American Heart Association. The institution of Dr. Chiang has received research support from Lundbeck. The institution of Dr. Chiang has received research support from Pfizer.